ICU Medical Inc ICUI
First person pronouns used in this Annual Report on Form 10-K, such as “we,” “us,” and “our,” refer to ICU Medical, Inc. (“ICU”) and its subsidiaries unless context requires otherwise. 10-K, Item 1
- Employees
- 13,000
- Headquarters
- San Clemente, CA
- CEO
- Vivek Jain
- Next results
- around Feb 18, 2027
Where each dollar of revenue went, FY2025
Revenue of $2.2B through the costs to a net profit of $732K · income statement of the 10-K
ICUI among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
13 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 19, 2026 against Feb 27, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Inventory growing faster than revenueInventory +5.3% ($584.7M to $615.9M) vs revenue -6.3% ($2.4B to $2.2B), +11.7 pts apart
-
Receivables -1.3% ($182.8M to $180.5M) vs revenue -6.3% ($2.4B to $2.2B), +5.1 pts apart
9 more checks with nothing to note
-
Cash from operations $179.8M vs net income $732,000 (FY ending Dec 31, 2025)
-
Same auditor in both 10-Ks: DELOITTE & TOUCHE LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Revenue Recognition - Chargeback Reserve
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
13 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
We derive a significant portion of our revenues from non-U.S. sales and from products manufactured at our non-U.S. facilities which are then imported to the U.S. We are therefore subject to risks of doing business in other countries, including those related to tariffs, retaliatory counter measures and further escalation of trade…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
In addition, modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of a PMA. The FDA requires every manufacturer to make this determination in the first…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
Foreign data protection laws, including the European Union General Data Protection Regulation (the "EU GDPR") and the United Kingdom General Data Protection Regulation (the "UK GDPR") (the EU GDPR and UK GDPR together referred to as the "GDPR", may also apply to health-related and other personal data obtained outside of the U.S. or in…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers, which went into effect on April 1, 2013, and will remain in effect through 2032, with…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $2.3B | $2.3B | $2.4B | $2.2B |
| Net income | −$74.3M | −$29.7M | −$117.7M | $732K |
| Operating cash flow | −$62.1M | $166.2M | $204.0M | $179.8M |
| Free cash flow | −$152.4M | $82.3M | $124.7M | $91.8M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$2.2B ▼ 6.3% in FY2025$732K in FY2025$91.8M ▼ 26.4% in FY2025
Recent filings
3 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 13, 2026ELISHA W FINNEY (Director) gave notice of a planned sale of 1,700 shares worth about $304K Form 144, approximate sale date Nov 13, 2026
-
8-KNov 5, 2026Quarterly results 8-K item 2.02
-
10-QNov 5, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
ICU Medical Inc, San Clemente, CA · from the 10-K filed Feb 19, 2026
First person pronouns used in this Annual Report on Form 10-K, such as “we,” “us,” and “our,” refer to ICU Medical, Inc. (“ICU”) and its subsidiaries unless context requires otherwise. ICU develops, manufactures and sells innovative medical products used in infusion therapy, vascular access, and vital care applications. Our team is focused on providing quality, innovation and value to our clinical customers worldwide.
- Headquarters
- San Clemente, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 5, 2026
- Incorporated in
- DE
Employees, at the top of the page: "At December 31, 2025, we had approximately 13,000 employees located in over 35 countries" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 19, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ICUI/export.csv") into a cell.